Maze Therapeutics director granted 18,000 options

Maze Therapeutics director Nancy C. Andrews received a grant of 18,000 stock options to buy common stock.

Accepted by SEC EDGAR 06/10/2026 - 04:23 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Maze Therapeutics director Nancy C. Andrews received a grant of 18,000 stock options to buy common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036. Following this grant, she holds 18,000 options.

The options will vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, provided she continues serving the company through that vesting date.

Insider Trade Summary

Grant/Award: 18,000 shares

Grant/Award 1 txn

Insider Andrews Nancy C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	18,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 18,000 contracts (Direct)

Footnotes (1)

1. F1. The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.

Key Figures

Options granted: 18,000 options Exercise price: $23.58 per share Total options after grant: 18,000 options +2 more

5 metrics

Options granted 18,000 options Stock Option (Right to Buy) grant to director

Exercise price $23.58 per share Exercise price for the 18,000 stock options

Total options after grant 18,000 options Total options held following this transaction

Expiration date June 7, 2036 Option expiration for this grant

Latest vesting date June 8, 2027 Latest possible vesting date, subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual stockholders meeting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 23.5800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date regulatory

"expiration_date: 2036-06-07T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual stockholders meeting regulatory

"the issuer's 2027 annual stockholders meeting"

continued service financial

"subject to the reporting person's continued service to the issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Maze Therapeutics (MAZE) director Nancy C. Andrews report on this Form 4?

Nancy C. Andrews reported receiving a grant of 18,000 stock options to acquire Maze Therapeutics common stock. These options are part of her director compensation and give her the right to buy shares at a fixed exercise price in the future.

What are the key terms of Nancy C. Andrews’ 18,000 Maze Therapeutics stock options?

The 18,000 options have an exercise price of $23.58 per share and an expiration date of June 7, 2036. They are options on Maze Therapeutics common stock, allowing potential future share purchases at this fixed price.

When do Nancy C. Andrews’ Maze Therapeutics stock options vest?

The options will vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027. Vesting is conditioned on her continued service to Maze Therapeutics through that vesting date.

How many Maze Therapeutics options does Nancy C. Andrews hold after this grant?

After this award, Nancy C. Andrews holds 18,000 stock options in Maze Therapeutics. This Form 4 only shows this specific grant and the resulting holdings, without detailing any additional option or share positions she may hold elsewhere.

Is Nancy C. Andrews’ Maze Therapeutics option grant an open-market purchase or a compensation award?

The Form 4 describes the transaction as a grant, award, or other acquisition with a transaction code A. This indicates a compensation-related stock option award, not an open-market purchase of Maze Therapeutics shares on a stock exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrews Nancy C

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.58	06/08/2026		A		18,000		(1)	06/07/2036	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)